ArticleCancer research communications2026
Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Application Value of Liquid Biopsy in Cancer MRD Detection and the Preliminary Clinical Significance of the TFx Value.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Low-pass whole-genome sequencing (LP-WGS) of circulating tumor DNA (ctDNA) is increasingly recognized for its utility in identifying somatic copy-number aberration (CNA). In this study, we analyzed LP-WGS ctDNA data from 73 pediatric patients with neuroblastic tumor and 11 healthy controls to explore diagnostic value of ctDNA CNA burden (including the genotypings) with a customized bioinformatics workflow. We found that a high baseline ctDNA CNA burden [tumor DNA fraction (TFx) ≥0.2%] was present in 36 of 41 patients (87.80%) with neuroblastoma, six of 22 patients (27.27%) with ganglioneuroblastoma, and three of 10 patients (30%) with ganglioneuroma. High baseline ctDNA CNA burden could predict high-risk neuroblastic tumors with an area under curve (AUC) of 0.95, sensitivity of 94.12%, and specificity of 100%. Frequent chromosomal copy-number changes, including chr17q gain, chr7 gain, chr3p loss, and chr11q loss, were found in ctDNA. Gain of chr17q demonstrated the highest diagnostic value with an AUC of 0.92, indicating strong sensitivity and specificity for detecting high-risk neuroblastic tumors. The homologous recombination deficiency score in the high- and intermediate-risk groups was significantly elevated compared with those in the low-/very low-risk group. The TFx levels and segmental alterations significantly decreased in patients with neuroblastic tumor who underwent chemotherapy, from median TFx = 13.82% before treatment to 0.24% after treatment (P < 0.0001). Our findings highlight the effectiveness of LP-WGS ctDNA CNA analysis as a promising approach for diagnosis and risk stratification of pediatric neuroblastic tumors and for monitoring chemotherapy response. Particularly, ctDNA analysis is minimally invasive, rapid, and cost-effective, which could bring additional benefits in pediatric practices. SIGNIFICANCE: Our results support the development of ctDNA CNA analysis as a robust and minimally invasive approach for early detection, molecular diagnosis, and risk stratification of peripheral neuroblastic tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.